Nucleic acid aptamer combined with MYO6 protein and application thereof
By developing nucleic acid aptamers with specific nucleotide sequences, the problem that the existing technology cannot specifically bind to MYO6 protein is solved, and high affinity and specific binding is achieved. It is suitable for the detection and treatment of MYO6 protein, improving diagnosis and treatment efficiency and sensitivity.
Patent Information
- Application Number
- CN202411257502.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing technology has not yet been able to specifically bind nucleic acid aptamers of the myosin VI (MYO6) protein, limiting its application in diagnosis and treatment.
A new nucleic acid aptamer has been developed, including specific nucleotide sequences (such as SEQ ID NO.1 and SEQ ID NO.2), and nucleic acid aptamers with high affinity and specific binding to MYO6 protein were screened through SELEX technology. ligands and improve their stability and detection efficiency through modification and labeling.
It achieves high affinity and specific binding of MYO6 protein, which is suitable for the detection, diagnosis and treatment of related diseases. It provides high sensitivity detection and purification methods for MYO6 protein, and is widely used in drug development and disease treatment.
Smart Images

Figure CN119040332A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical technology, and in particular relates to a nucleic acid aptamer binding to MYO6 protein and an application thereof. Background Art
[0002] Myosin VI (MYO6) is a non-traditional myosin molecular motor with unique functions in eukaryotic cells. It is different from other myosins because it is the only myosin that is transported in the reverse direction along the microfilaments (from the plus end to the minus end of the microfilaments). MYO6 plays an important role in many cellular processes such as autophagy and endocytosis pathways. The loss or abnormality of its function is associated with a variety of human diseases, such as hypertrophic cardiomyopathy, cervical cancer, prostate cancer, deafness, and brain astrogliosis.
[0003] More and more studies have found that MYO6 is related to the occurrence, invasion and metastasis of tumors, and is highly expressed in some tumor tissues (such as ovarian cancer, prostate cancer, glioma, breast cancer, hepatocellular carcinoma, lung cancer, gastric cancer, leukemia, etc.). At the same time, MYO6 is lowly expressed in normal cells, which makes MYO6 a very attractive target protein or an important target for tumor drug development. It is of great significance to achieve qualitative and quantitative detection and purification of MYO6, and to develop reagents or drugs for the diagnosis and treatment of abnormal MYO6 expression.
[0004] Aptamers are a class of single-stranded oligonucleotides that can bind to specific target molecules (such as small molecules, proteins, nucleic acids, cells or whole organisms) with high specificity through molecular recognition. They are usually screened from random nucleotide sequence libraries through a ligand screening process called exponential enrichment (Systematic Evolution of Ligands by EXponential enrichment, SELEX). It has high specificity and high affinity, and compared with antibodies, it has a smaller molecular weight, better stability, is easy to synthesize and modify, has no immunogenicity, has a short production cycle, and can be synthesized artificially, eliminating a series of processes such as animal immunization, feeding, protein extraction and purification. Therefore, it has a wide range of applications, including but not limited to drug development, biosensors, diagnostic tools and therapeutic agents.
[0005] However, there is no report on nucleic acid aptamers that can specifically bind to MYO6 protein. Summary of the invention
[0006] In view of this, the primary purpose of the present invention is to provide a nucleic acid aptamer that binds to the MYO6 protein, which has high binding affinity with the MYO6 protein, good specificity, small molecular weight, stable chemical properties, and is easy to store and label. The present invention also provides a conjugate or derivative of the nucleic acid aptamer, a screening method and application thereof.
[0007] In order to achieve the above object, the present invention adopts the following technical solutions:
[0008] The first aspect of the present invention provides a nucleic acid aptamer that binds to the MYO6 protein. The nucleic acid aptamer can bind to the MYO6 protein with high affinity and high specificity, and can be used for applications in detection, diagnosis, imaging, and treatment of the MYO6 protein.
[0009] In some embodiments of the present invention, the sequence of the nucleic acid aptamer includes the nucleotide sequence shown in SEQ ID NO.1 or 2, which are respectively named GP-1 and GP-2 herein, wherein the nucleic acid aptamer GP-2 is obtained by truncating the nucleotide sequence of the nucleic acid aptamer GP-1.
[0010] In some preferred embodiments of the present invention, the sequence of the nucleic acid aptamer is shown in SEQ ID NO. 1 or 2. More preferably, the sequence of the nucleic acid aptamer is shown in SEQ ID NO. 2. Experiments herein have confirmed that the key domain of the nucleic acid aptamer that can specifically bind to the MYO6 protein is in GP-2 (SEQ ID NO. 2).
[0011] In some other embodiments of the present invention, the sequence of the nucleic acid aptamer includes a nucleotide sequence having at least 30%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99% homology to the nucleotide sequence shown in SEQ ID NO.1 or 2. Herein, it refers to a sequence in which one or more nucleotides in the nucleotide sequence shown in SEQ ID NO.1 or 2 are replaced, deleted or added. As long as it still has the function of specifically binding to the MYO6 protein, it also falls within the scope of protection of the present invention.
[0012] In some other embodiments of the present invention, the nucleic acid aptamer includes an RNA sequence transcribed from the nucleotide sequence shown in SEQ ID NO. 1 or 2. The transcription described herein includes the genetic code in the DNA sequence being transcribed into RNA; and the RNA can then be translated into protein.
[0013] In some other embodiments of the present invention, the nucleic acid aptamer comprises a sequence that can hybridize with the nucleotide sequence shown in SEQ ID NO. 1 or 2. Generally speaking, hybridization as described herein refers to a process in which two single-stranded polynucleotides non-covalently bind to form a stable double-stranded polynucleotide.
[0014] In other embodiments of the present invention, it is optional to modify a certain position or multiple positions of the nucleic acid aptamer, and the "multiple" mentioned herein refers to more than two. The modification can be, for example, at least one of phosphorylation, methylation, amination, sulfhydrylation, replacement of oxygen with sulfur, replacement of oxygen with selenium, and isotopization. As long as the modified sequence still has the function of specifically binding to the MYO6 protein, for example, it has an affinity with the MYO6 protein that is equal to or higher than that of the parent nucleotide sequence before modification, or although the affinity is not significantly improved but has higher stability, etc., it also belongs to the scope of protection of the present invention.
[0015] The second aspect of the present invention provides a nucleic acid aptamer conjugate or derivative that binds to MYO6 protein.
[0016] The conjugate described herein refers to a conjugate formed by connecting the nucleic acid aptamer described in the first aspect of the present invention to a label, and its sequence contains the sequence of the nucleic acid aptamer described in the first aspect of the present invention. Wherein, the label connected to the nucleic acid aptamer includes one or more of a radioactive substance, a therapeutic substance, biotin, an enzyme label, a fluorescent label, a nucleic acid probe, a nanoluminescent material, a small peptide or siRNA.
[0017] Among them, radioactive materials mainly refer to radioactive materials commonly used in the art that can be used for isotope labeling technology. Specific examples include but are not limited to 2H (deuterium-labeled D), 13C, 14C, 15N, 17O, 18O, 34S, etc.
[0018] Therapeutic substances refer to substances used to treat diseases, alleviate symptoms or improve health conditions. Specific examples include but are not limited to chemically synthesized or biologically derived drugs.
[0019] Enzyme labeling refers to a marker with enzyme activity. By combining it with aptamers, the application efficiency of aptamers in biological detection can be significantly improved, such as using enzyme catalysis to generate measurable signals, which are usually manifested as color changes, fluorescence enhancement or luminescence phenomena, which are convenient for quantitative analysis. The sensitivity and specificity of detection can be significantly improved by enzyme labeling. In addition, since the enzyme catalysis reaction can amplify the signal, trace target molecules can also be accurately identified. In general, the enzyme labeling applied to aptamers specifically includes horseradish peroxidase (HRP), β-galactosidase (β-galactosidase) or proteinase G (Proteinase G), but is not limited to this.
[0020] Fluorescent labeling refers to a label that can emit fluorescence, and specific examples include but are not limited to fluorescent proteins (such as GFP, etc.), FAM, FITC, rhodamine, Texas Red, Cy series dyes, etc.
[0021] The nucleic acid probe may be, for example, digoxigenin.
[0022] Nano luminescent materials can be, for example, quantum dots, polymer nanoparticles, etc.
[0023] In some preferred embodiments of the present invention, preferably, fluorescein is used for labeling.
[0024] It is understood that the labels that can be used to connect to the nucleic acid aptamer herein are all known in the art, and the connection methods are well known in the art, such as covalent connection, disulfide bond connection, amino connection, etc. These substances can be connected to the nucleic acid aptamer at any one or both of the 5' end and the 3' end of the nucleic acid aptamer, and under certain conditions, they can be connected intermolecularly.
[0025] As long as these conjugates have the function of specifically binding to the MYO6 protein, have an affinity to the MYO6 protein that is equal to or higher than that of the parent nucleotide sequence before connection, or have a higher stability even though the affinity is not significantly improved, they also fall within the scope of protection of the present invention.
[0026] The derivatives described herein refer to those formed by modifying the nucleic acid aptamer or nucleic acid aptamer conjugate described in the first aspect of the present invention.
[0027] In the present invention, the modification includes a phosphorothioate backbone derived from the backbone of the nucleotide sequence of the aptamer or aptamer conjugate; or a peptide nucleic acid modified from the nucleotide sequence of the aptamer or aptamer conjugate. As long as the modified derivative has the function of specifically binding to the MYO6 protein, it also falls within the scope of protection of the present invention.
[0028] Among them, the phosphorothioate backbone herein has a definition generally recognized by those skilled in the art, which means that the non-bridging oxygen atoms of the phosphodiester backbone of RNA and DNA nucleic acid aptamers can be replaced by one or two sulfur atoms, respectively, to produce a phosphorothioate backbone with a phosphorothioate or phosphorodithioate bond. It is known to those skilled in the art that such a phosphorothioate backbone has an increased binding affinity to its target and an enhanced resistance to nuclease degradation.
[0029] The peptide nucleic acid (PNA) described in this article has the definition generally recognized by those skilled in the art, and refers to an oligonucleotide whose backbone is composed of N-(2-aminoethyl)-glycine repeating units linked by peptide bonds, wherein different nitrogenous bases are linked to the main chain through methylene bonds (-CH2-) and carbonyl groups (-(C=O)-).
[0030] It is understandable that the modified nucleic acid aptamers, nucleic acid aptamer conjugates or derivatives described above all have molecular structures, physicochemical properties and functions that are substantially the same or similar to those of the parent nucleic acid aptamer, that is, they can all be used for specific binding to the MYO6 protein.
[0031] The third aspect of the present invention provides a method for screening nucleic acid aptamers binding to MYO6 protein, which is based on SELEX technology and comprises the following steps:
[0032] (1) synthesizing a random single-stranded DNA library and providing primers, wherein the DNA library includes a random single-stranded DNA as shown in TCCAGCACTCCACGCATAAC-36N-GTTATGCGTGCTACCGTGAA, wherein 36N represents a sequence formed by connecting 36 arbitrary nucleotide bases; the sequences of the primers are shown in SEN ID NOs. 3 to 6;
[0033] (2) Magnetic bead screening: Perform at least 4 rounds of counter-screening and screening, and add serum starting from the 4th round;
[0034] In a further embodiment, the step (2) of adding serum in the fourth round comprises the following steps: adding 2% serum in the fourth round and adding 5% serum in the fifth round; the serum is human serum.
[0035] The other steps are all well-known process means in the art. The specific process flow conditions can be operated according to the methods well-known in the art or based on the instructions of the reagents, kits, etc. used, and will not be elaborated here one by one.
[0036] A fourth aspect of the present invention provides a product for detecting MYO6 protein, wherein the product contains the nucleic acid aptamer or nucleic acid aptamer conjugate or derivative as described above, or a nucleic acid aptamer screened by the method described above.
[0037] A fifth aspect of the present invention provides a product for purifying MYO6 protein, wherein the product contains the nucleic acid aptamer or nucleic acid aptamer conjugate or derivative as described above, or a nucleic acid aptamer screened by the method described above.
[0038] The products described in the present invention are mainly in vitro products for non-disease diagnosis or treatment purposes, such as preparations, test strips, kits, chips or chromatographic detection devices. Such products contain the nucleic acid aptamers or nucleic acid aptamer conjugates or derivatives described above, so as to achieve specific binding with MYO6 protein, so as to achieve the purpose of detecting MYO6 protein or purifying MYO6 protein.
[0039] It is understandable that these products may also include MYO6 protein or other reagents required for purification, such as buffer solutions, cleaning solutions, etc., as needed. They can be configured as needed and will not be elaborated here.
[0040] The specific detection or purification varies depending on the technology used, but the core is to contact the nucleic acid aptamer or nucleic acid aptamer conjugate or derivative with the MYO6 protein to achieve detection or purification.
[0041] In a sixth aspect, the present invention provides a drug for treating a disease caused by abnormal expression of MYO6 protein, which contains the nucleic acid aptamer described above, or the nucleic acid aptamer conjugate or derivative described above, or a nucleic acid aptamer screened by the method described above.
[0042] The drug contains the aforementioned nucleic acid aptamer or the aforementioned nucleic acid aptamer conjugate or derivative, and therefore can target MYO6 protein and specifically bind to MYO6 protein, thereby being able to treat diseases caused by abnormal expression of MYO6 protein. In the present invention, the abnormal expression of MYO6 protein refers to high expression of MYO protein in cells or tissues; the disease can be a tumor caused by high expression of MYO protein, such as ovarian cancer, prostate cancer, glioma, breast cancer, hepatocellular carcinoma, lung cancer, gastric cancer or leukemia, but is not limited thereto. .
[0043] It is understandable that, in the present invention, the medicine further contains any pharmaceutically acceptable excipients and / or carriers.
[0044] In some specific implementation cases of the present invention, the pharmaceutically acceptable auxiliary materials and / or carriers include but are not limited to at least one of diluents, binders, surfactants, adsorption carriers, lubricants, fillers, and disintegrants.
[0045] Among them, in some specific implementation cases of the present invention, for example, the diluent may be lactose, sodium chloride, glucose, urea, starch, water, etc., but not limited thereto. For example, the binder may be starch, pregelatinized starch, dextrin, maltodextrin, sucrose, gum arabic, gelatin, methyl cellulose, carboxymethyl cellulose, ethyl cellulose, polyvinyl alcohol, polyethylene glycol, polyvinyl pyrrolidone, alginic acid and alginate, xanthan gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, etc., but not limited thereto. For example, the surfactant may be: polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid monoglyceride, hexadecanol, etc., but not limited thereto. For example, the adsorption carrier may be starch, lactose, bentonite, silica gel, kaolin, bentonite, etc. For lubricant, for example, zinc stearate, glyceryl monostearate, polyethylene glycol, talcum powder, calcium and magnesium stearate, polyethylene glycol, boric acid powder, hydrogenated vegetable oil, sodium stearyl fumarate, polyoxyethylene monostearate, monolauric sucrose acid ester, sodium lauryl sulfate, magnesium lauryl sulfate, magnesium dodecyl sulfate, etc., but are not limited to this. For filler, for example, mannitol, xylitol, sorbitol, maltose, erythrose, microcrystalline cellulose, polymerized sugar, coupling sugar, glucose, lactose, sucrose, dextrin, starch, sodium alginate, laminarin powder, agar powder, calcium carbonate, sodium bicarbonate, etc., but are not limited to this. For disintegrant, for example, cross-linked vinyl pyrrolidone, sodium carboxymethyl starch, low-substituted hydroxypropyl methyl, cross-linked sodium carboxymethyl cellulose, soybean polysaccharide, etc.
[0046] In addition, in the present invention, the auxiliary material and / or carrier may also be at least one of a stabilizer, a buffer, an isotonic agent, a pH regulator or a chelating agent.
[0047] The selection of specific excipients and / or carriers can be carried out according to the dosage form of the drug. When specifically selected, they can be compatible with the active substance, or can effectively improve the stability and solubility of the active ingredients contained in the drug, or can change the release rate and absorption rate of the active substance, thereby ensuring or enhancing the administration effect of the active ingredient. In the present invention, the dosage form of the drug is not particularly limited, and any dosage form known in the art that is conducive to administration can be adopted, for example, it can be: aqueous solution injection, powder injection, pill, powder, tablet, granule, capsule, etc. The beneficial administration described herein refers to being able to improve the therapeutic effect or improve the bioavailability or reduce the toxic side effects or improve the patient's adaptability, etc.
[0048] The seventh aspect of the present invention provides the use of the nucleic acid aptamer or nucleic acid aptamer conjugate or derivative described above or the nucleic acid aptamer screened by the method described above in the preparation of a product for detecting or purifying MYO6 protein. The product has the same meaning as described above and will not be described one by one here.
[0049] In an eighth aspect, the present invention provides the use of the nucleic acid aptamer or nucleic acid aptamer conjugate or derivative as described above, or the nucleic acid aptamer obtained by screening using the method described above, in the preparation of a drug for treating a disease caused by abnormal expression of MYO6 protein. The drug described here has the same meaning as described above, and will not be elaborated here one by one.
[0050] Beneficial effects of the present invention:
[0051] The nucleic acid aptamer provided by the present invention can specifically bind to MYO6 protein, and has the advantages of high affinity, small molecular weight, stable chemical properties, easy storage and labeling, etc. The nucleic acid aptamer can be used in the detection, diagnosis, imaging and treatment related to MYO6 protein, such as the preparation of products for purification or high-sensitivity detection of MYO6 protein; or, it can be used to prepare drugs for treating diseases caused by abnormal expression of MYO6 protein, etc., and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 This is a schematic diagram of the binding ability of the enriched library obtained in the third and fifth rounds of screening with the target protein detected by flow cytometry in Example 1.
[0053] Figure 2 This is a schematic diagram of the affinity detection results between nucleic acid aptamer GP-1 and MYO6 protein in Example 2.
[0054] Figure 3 This is a schematic diagram of the affinity detection results between nucleic acid aptamer GP-2 and MYO6 protein in Example 3.
[0055] Figure 4 This is a schematic diagram of the specificity research results of the nucleic acid aptamer GP-1 in Example 5.
[0056] Figure 5 This is a schematic diagram of the specificity study results of the nucleic acid aptamer GP-2 in Example 5.
[0057] Figure 6 This is a schematic diagram of the results of the dot hybridization experiment using the nucleic acid aptamer GP-1-Biotin to detect MYO6 protein and control protein in Example 6.
[0058] Figure 7 This is a schematic diagram of the results of the dot hybridization experiment using the nucleic acid aptamer GP-1-Biotin in Example 6 to detect different concentrations of MYO6 protein. DETAILED DESCRIPTION
[0059] Embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.
[0060] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. In addition, unless otherwise specified, methods that do not specifically record conditions or steps are conventional methods, and the reagents and materials used can be obtained from commercial sources.
[0061] Example 1 Screening of ssDNA nucleic acid aptamers binding to MYO6 protein
[0062] This example provides a method for screening ssDNA nucleic acid aptamers that bind to MYO6 protein, which specifically includes the following steps:
[0063] 1. Synthesize random single-stranded DNA library and provide primers:
[0064] A random single-stranded DNA library and primers are provided, wherein the DNA library includes a random single-stranded DNA as shown in TCCAGCACTCCACGCATAAC-36N-GTTATGCGTGCTACCGTGAA (5'→3'), wherein 36N represents a sequence formed by connecting 36 arbitrary nucleotide bases. The DNA library was commissioned to be synthesized by Sangon Biotech (Shanghai) Co., Ltd.
[0065] The primer information is shown in Table 1. The primers were commissioned to be synthesized by Nanjing GenScript Biotechnology Co., Ltd.
[0066] Table 1 Primers and sequence information
[0067] Primer name Sequence information (5'→3') Sequence number Lib18S1 TCCAGCACTCCACGCATAAC SEQ ID NO.3 Lib18A2 TTCACGGTAGCACGCATAAC SEQ ID NO.4 Lib18-FAM-S1 FAM-TCCAGCACTCCACGCATAAC SEQ ID NO.5 Lib18-Biotin-A2 Biotin-TTCACGGTAGCACGCATAAC SEQ ID NO.6
[0068] In Table 1, S in the primer name represents a forward primer, and A in the primer name represents a reverse primer.
[0069] The primers were prepared into 100 μM stock solution with ddH2O and stored at -20°C for future use.
[0070] 2. Magnetic bead screening
[0071] The magnetic bead method was used for screening. In this embodiment, a total of 5 rounds of screening were performed. The screening process of each round is shown in Table 2.
[0072] Table 2 Screening process of MYO6 protein nucleic acid aptamers
[0073]
[0074]
[0075] The specific screening process is as follows:
[0076] (1) Carboxyl magnetic beads to immobilize MYO6 protein
[0077] Take 50 μl of carboxyl magnetic beads (Jiangsu Zecheng Biotechnology Co., Ltd., product number: FM2221), wash them four times with 200 μl of ultrapure water, fish the magnetic beads with a magnet, and remove the supernatant; take 100 μl each of the prepared NHS (N-hydroxysuccinimide; 0.1 M aqueous solution) and EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; 0.4 M aqueous solution), mix equal volumes, add to the magnetic beads, incubate at 25°C for 20 minutes to activate the carboxyl groups on the surface of the magnetic beads, and wash the magnetic beads once with ddH2O for use.
[0078] Take 10 μl of MYO6 protein (purchased from Younozhen, P63518PA, concentration is 1 mg / ml), add 90 μl of sodium acetate (pH 5.0, 10 mM), mix well, and add to the above-mentioned activated magnetic beads; incubate on a vertical mixer at 25°C for 60 minutes, and the MYO6 protein is coupled to the surface of the magnetic beads through the amino groups on the protein surface.
[0079] After the coupling is completed, the test tube is placed on a magnetic rack, the supernatant is discarded, 100 μl of ethanolamine (pH 8.5, 1 M) is added to the magnetic beads, and incubated on a 25°C vertical mixer for 10 minutes to block the unreacted activation sites on the surface of the magnetic beads; the test tube is then placed on a magnetic rack and the blocking solution is discarded; the magnetic beads are washed four times with DPBS (200 μl) and labeled as MB-MYO6.
[0080] (2) Counter-screening and screening
[0081] Preparation of reverse screening magnetic beads: The His peptide was coupled to the magnetic beads. The His peptide was synthesized by GenScript Biotech Co., Ltd. and consisted of 9 consecutive histidines. The steps for coupling the His protein were the same as those for coupling the MYO6 protein. The concentration of the His peptide was 1 mg / ml and it was diluted with a 10 mM sodium acetate solution at pH 4.5. The specific steps were as follows: take 20 μl of the His peptide, add 80 μl of sodium acetate solution (pH 4.5, 10 mM) and mix well. The remaining steps were the same as those for coupling the MYO6 protein. The coupled magnetic beads were labeled MB-His.
[0082] Library dissolution and denaturation treatment: Take 1OD random single-stranded nucleotide library, centrifuge at 14000rpm for 5 minutes, centrifuge the library to the bottom of the tube, dissolve it to 10μM with DPBS buffer, mix it and dispense it into PCR tubes for denaturation treatment. The specific processing process is as follows: set the PCR instrument program to 95℃ for 10 minutes. The purpose of this step is to unwind the folded chain, then keep it at 4℃ for 5 minutes, and then balance it to room temperature; add the treated library to 50μl MB-His magnetic beads, mix it and incubate it at room temperature for a period of time on a vertical mixer; place it on a magnetic stand, collect the supernatant, mark it as pool-, and use the supernatant as a single-stranded nucleic acid library for positive screening with MB-MYO6 magnetic beads; in each round of magnetic bead screening, use MB-His for reverse screening before conducting a positive screening targeting MYO6 protein, and use the reverse screening supernatant as a single-stranded nucleotide library for positive screening with MB-MYO6 magnetic beads. Specifically, the library pool- after counter-screening was added to 50 μl MB-MYO6 magnetic beads and incubated at 25°C on a vertical mixer for 40 minutes; placed on a magnetic stand, the supernatant was aspirated and discarded, the magnetic beads were retained, and the magnetic beads were washed 4 times with 200 μl DPBS; finally, 200 μl ddH2O was added to the washed magnetic beads, boiled in a boiling water bath for 10 minutes, and the supernatant was collected and marked as elution-MYO6.
[0083] The nucleic acid molecules in elution-MYO6 were used as templates and amplified by ordinary PCR. The method is as follows: add all the template elution-MYO6 to 2ml PCR mix and mix well, divide the mixture of template and PCR mix into 100μl / tube and add it to the PCR tube, and the amplification conditions are as follows: 95℃ pre-denaturation for 3 minutes, 95℃ denaturation for 30 seconds, 60℃ annealing for 30 seconds, 72℃ extension for 30 seconds, among which, denaturation, annealing and extension are performed for 20 cycles in total, and stored at 4℃. The first and second round libraries were amplified by PCR three times, and the upstream and downstream primers of PCR1 were Lib18-S1 (1.5 μM) and Lib18A2 (1.5 μM), respectively, and amplified for 10 cycles according to the above amplification conditions; then PCR2 was performed, using a small part of the product of PCR1 as a template, and the upstream and downstream primers were Lib18-FAM-S1 (1.5 μM) and Lib18A2 (1.5 μM), respectively, and amplified for 8, 10, 12, 14, 16, 18, and 20 cycles according to the above amplification conditions, and denatured polyacrylamide was used to amplify the amplification products. Amide gel electrophoresis was used to check the quality of the above cycle numbers (whether there was nonspecific amplification, which cycle number was larger, etc.); PCR3 was prepared in large quantities based on the results of PCR2, and the upstream and downstream primers were Lib18-S1 (1.5μM) and Lib18-Biotin-A2 (1.5μM); the following 3-5 rounds of PCR were directly used as templates with elution-MYO6 solution, Lib18-S1 (1.5μM) and Lib18-Biotin-A2 (1.5μM) as upstream and downstream primers, and amplified for 20 cycles. Among them, the primers contained FAM for observation, and the purpose of containing Biotin was to prepare single strands. The PCR raw materials were prepared with dNTPs (P031-02) purchased from Novozymes and rtaq enzyme (R500Z) purchased from Takara Biotech.
[0084] The amplified product was purified using commercially purchased Tiandirenhe SA magnetic beads (SM017100) to prepare the secondary library for the next round of screening. 1 / 5 volume of sodium chloride (4M) was added to 2mL of PCR product, and then 160μl of SA magnetic beads that had been washed with DPBS and the supernatant removed were added. After incubation on a shaker at room temperature for 30 minutes, the PCR product supernatant was removed; then the magnetic beads were washed three times with DPBS containing 0.02% Tween20, 100μl of sodium hydroxide solution (40mM) was added after the supernatant was removed, and the magnetic beads were removed by magnetic attraction after three minutes of incubation. Then 4μl of hydrochloric acid (1M) was added to the supernatant to neutralize the single strand, and then 104μl of 2×DPBS was added to dilute and neutralize the salt concentration, and finally 208μl of the secondary library dissolved in 1×DPBS was obtained, which can be used as the library for the next round of screening.
[0085] The magnetic bead method was repeated for 5 rounds of screening. Each operation used the secondary library obtained in the previous operation as the starting nucleic acid library. After the library was denatured and renatured, it was incubated with MB-MYO6 magnetic beads. During the screening process, the enrichment of the library was judged according to the QPCR Cq value of elution during each round of positive and negative screening. If the number of templates eluted from each round of positive screening increased with the increase of screening rounds (Cq advanced) and the number of templates eluted in the last round was more than 100 times the number of templates in the first round, the screening was stopped.
[0086] Figure 1 The retention rate of each round of molecules calculated based on the elution Cq values of the positive and negative screens showed that the retention rate of the positive screen gradually increased, and it can be seen that the library is effectively enriched. The flow cytometer CytoFLEX was used to detect the changes in the recognition ability of the DNA single-stranded library for the MYO6 protein. When the recognition ability of the DNA single-stranded library for the MYO6 protein meets the requirements, that is, the binding ability of the screened DNA single-stranded library with the target protein is higher than that of the library at the beginning of the screening ( Figure 1 ), Figure 1 P3 and P5 represent the libraries obtained in the third and fifth rounds of screening, respectively. It can be seen that the library obtained in the third round has a higher affinity with the target than the starting library, and there is no obvious increase in the flow displacement of P5 compared with P3, which meets the sequencing requirements. The obtained library was analyzed by high-throughput sequencing.
[0087] 3. Analysis and identification of nucleic acid aptamers obtained after screening: After high-throughput sequencing analysis of the obtained enriched library products, several sequences are selected and commissioned to Genewise Biotechnology (Jiangsu) Technology Co., Ltd. for synthesis and affinity testing.
[0088] In subsequent tests, one sequence was identified as having strong binding ability, which is a nucleic acid aptamer having a nucleotide sequence as shown in SEQ ID NO.1, and is named GP-1 herein.
[0089] Example 2 Surface Plasmon Resonance (SPR) Detection of the Affinity of MYO6 Protein Aptamer GP-1 and MYO6 Protein
[0090] In this example, Suzhou GeneWeiZhi Biotechnology Co., Ltd. was commissioned to synthesize nucleic acid aptamer GP-1 (SEQ ID NO. 1), which was diluted with DPBS buffer to 31.25 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, and 1000 nM for use.
[0091] 1. MYO6 protein (purchased from Younuozhen, P63518PA, concentration of 1 mg / ml) was coupled to the second channel of the SPR chip CM5 surface. The specific method is as follows: Equal volumes of EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; 0.4M aqueous solution) and NHS (N-hydroxysuccinimide; 0.1M aqueous solution) were mixed and injected with 50 μl to activate the chip at a flow rate of 5 μl / min. MYO6 protein was diluted with sodium acetate (pH4.5, 10mM) to a final concentration of 50 μg / mL and then injected with an injection volume of 50 μL, a flow rate of 5 μL / min, and the amount of MYO6 protein coupled was 12723Ru. After the injection was completed, ethanolamine was injected to block the chip at a flow rate of 5 μL / min and 50 μL was injected. Channel 1 was treated as above, and the steps of coupling His small peptide, activation and blocking were exactly the same as those of the control channel.
[0092] 2. Detection: Use a surface plasmon resonance instrument (GE Healthcare, model: Biacore 8K) to set the detection parameters. The diluted two aptamer samples flow through channels 1 and 2 in turn. The program for each aptamer is as follows: injection 20 μL / min, time 2 minutes, dissociation 20 μL / min, time 2 minutes, regeneration 1.5 M NaCl 30 μL / min, time 30 seconds, and the diluted GP-1 nucleic acid aptamer is injected.
[0093] The affinity test data of nucleic acid aptamer GP-1 and MYO6 protein are shown in Figure 2 , the KD values are shown in Table 3 below.
[0094] Table 3 Affinity results of nucleic acid aptamer GP-1 and MYO6 protein
[0095] Aptamers length Affinity KD for MYO6 protein (nM) SEQ ID NO.1(GP-1) 76 17.2
[0096] Example 3 Surface Plasmon Resonance (SPR) Detection of the Affinity of Nucleic Acid Aptamer GP-2 (SEQ ID NO. 2) and MYO6 Protein
[0097] In this example, Suzhou Jinweizhi Biotechnology Co., Ltd. was commissioned to synthesize nucleic acid aptamer GP-2 (SEQ ID NO. 2), which was diluted with DPBS buffer to 32.5 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, and 1000 nM for use.
[0098] The same method as in Example 3 was used to fix the MYO6 protein to the SPR chip CM5 (Situofan, BR100530) for testing. The MYO6 protein (purchased from Younuozhen, P63518PA, concentration of 1 mg / ml) was coupled to the 2nd channel on the chip surface, and the coupling amount was 10470RU; the His small peptide (Nanjing GenScript Biotechnology Co., Ltd.) was coupled to the 1st channel, and the coupling amount was 463.1RU. The detection parameters were set using a surface plasmon resonance instrument (GE Healthcare, model: Biacore 8K), and the diluted aptamer sample in step 1 of Example 3 was injected, and flowed through channels 1 and 2 in sequence. The procedure for each aptamer was as follows: injection 20 μL / min, time 2 minutes, dissociation 20 μL / min, time 2 minutes, regeneration 1.5M NaCl 30 μL / min, time 30 seconds.
[0099] The affinity test data of nucleic acid aptamer GP-2 and MYO6 protein are shown in Figure 3 , KD values are shown in Table 4.
[0100] Table 4 Affinity results of nucleic acid aptamer GP-2 and MYO6 protein
[0101] Aptamers length Affinity KD for MYO6 protein (nM) SEQ ID NO.2(GP-2) 56 20.9
[0102] Figure 3 The results in Table 4 indicate that the nucleic acid aptamer GP-2 has a strong binding with the MYO6 protein detected by the SPR instrument, but has no binding with the control protein His.
[0103] And it can be seen from the data in Tables 3 and 4 that both nucleic acid aptamers GP-1 and GP-2 have very good affinity with MYO6 protein.
[0104] Example 4 Comparison of affinity between GP-1 before and after truncation and MYO6
[0105] In this example, GP-1 was truncated to obtain a nucleic acid aptamer with a nucleotide sequence as shown in SEQ ID NO. 2, and after verification, it had an ideal affinity for binding to MYO6, and was named GP-2 herein. The changes in the recognition ability of GP-1 and GP-2 to MYO6 protein were detected by SPR in the same manner as in Example 3, and the affinity of the nucleic acid aptamer containing 56 nucleotides after truncation to binding to MYO6 was verified to be comparable with that before truncation.
[0106] The experimental results show that the affinity of nucleic acid aptamer GP-1 is 17.2nM ( Figure 2 ), the truncated aptamer GP-2 (SEQ ID NO.2) contains 56 nucleotides, and its affinity to MYO6 is 20.9nM ( Figure 3), which is consistent with the affinity of the aptamer GP-1 before truncation, indicating that the core region of the key structural domain of the aptamer GP-1 is in GP-2, and the affinity of the aptamer remains consistent after truncation.
[0107] Example 5 Study on the specificity of nucleic acid aptamers GP-1 and GP-2
[0108] In this embodiment, BSA (purchased from Shenggong Bioengineering (Shanghai), item number A600332), IgG protein (purchased from Jingjie Biotechnology, item number: ABT-9112), IL-15 protein (purchased from Jingjie Biotechnology, item number: ABT-9076), ROR1 protein (item number: 13968-H08H, purchased from Sino Biological) are used to replace MYO6 protein, and the same steps as the method of fixing MYO6 protein to SPR chip CM5 for testing in Example 3 are used to couple BSA, IgG protein, IL-15 protein and ROR1 protein to the second channel of four Channals on the surface of SPR chip CM5, respectively, and the coupling amounts are 2079RU, 2051RU, 3723RU and 8075RU, respectively. The diluted nucleic acid aptamers GP-1 and GP-2 are injected in sequence.
[0109] Among them, the affinity test data of nucleic acid aptamer GP-1 and BSA, IgG protein, IL-15 protein and ROR1 protein are shown in Figure 4 The affinity test data of nucleic acid aptamer GP-2 and BSA, IgG protein, IL-15 protein and ROR1 protein are shown in Figure 5 .Depend on Figure 4 and Figure 5 It can be seen that both nucleic acid aptamers GP-1 and GP-2 cannot bind to BSA, IgG protein, IL-15 protein and ROR1 protein, indicating that nucleic acid aptamers GP-1 and GP-2 have very good specificity for MYO6 protein.
[0110] Example 6 Detection of MYO6 protein by dot blot hybridization based on nucleic acid aptamer GP-1
[0111] The steps of the dot hybridization experiment performed in this embodiment are as follows:
[0112] 1. Take two 8cm×2cm nitrocellulose membranes (nitrocellulose membrane, 0.2μm, GE Amersham, catalog number 10600001), dilute MYO6 protein, control protein BSA, control protein His peptide and A6NJ protein (catalog number: P0010, purchased from Jingjie Bio) to 0.5mg / ml with DPBS, spot 2μl of each sample on the nitrocellulose membrane and air-dry for 30 minutes.
[0113] In addition, MYO6 protein was diluted with DPBS to 1.200 mg / ml, 0.600 mg / ml, 0.300 mg / ml, 0.150 mg / ml, and 0.075 mg / ml, respectively. 2 μl of each sample was spotted on a nitrocellulose membrane and air-dried for 30 minutes.
[0114] 2. After drying, block with 10% calf serum at room temperature for 1 hour. After blocking, wash with DPBST (DPBS containing 2 / 10,000 tween20) for 3 times and aspirate clean.
[0115] 3. Biotin-modified aptamer GP-1 (biotin modified at the 5' end) was added to the 2+ The diluted aptamer was diluted to 1 μM with DPBS, and then the diluted aptamer was incubated with the protein on the nitrocellulose membrane on a shaker at room temperature for 30 minutes.
[0116] 4. After incubation, use 5mM Mg 2+ Wash three times with DPBST, 5 minutes each time on a shaker.
[0117] 5. Add 5 mM Mg 2+ HRP-labeled streptavidin (purchased from Beyotime, catalog number A0303) was diluted 1:2000 in DPBST and incubated on a shaker at room temperature for 30 minutes.
[0118] 6. Contains 5mM Mg 2+ Wash three times with DPBST, placing on a shaker for 2 minutes each wash.
[0119] 7. Add color developing solution (BeyoECL Star ultra-sensitive ECL chemiluminescence kit, purchased from Beyotime, item number P0018A, solution A and solution B are the solutions provided by the kit) at a ratio of solution A: solution B = 1:1 (v / v), and develop the color at room temperature in the dark for 5 minutes.
[0120] 8. Imaging system observation and photography: The instrument used is ImageQuant from GE Healthcare Life Sciences TM LAS 4000 digital imaging system.
[0121] Figure 6 The results of the spot hybridization experiment of MYO6 protein and other control proteins are shown, where 1 is MYO6 protein, 2 is BSA protein, 3 is His peptide, and 4 is A6NJ protein; compared with the spots of the control proteins BSA, His peptide, and A6NJ, the MYO6 protein has obvious color development, which shows that biotin-modified GP-1 can be used for the detection of MYO6 protein by membrane hybridization, and does not bind to the control proteins BSA protein, HIS peptide, and A6NJ protein. Figure 6It can be seen that the nucleic acid aptamer GP-1 provided by the present invention can only bind to MYO6 protein, and cannot bind to other proteins such as BSA, HIS small peptide, and A6NJ protein, and has high specificity.
[0122] Figure 7 The dot hybridization experiment of different concentrations of MYO6 protein (1.200mg / ml, 0.600mg / ml, 0.300mg / ml, 0.150mg / ml, 0.075mg / ml) is shown. It can be seen that the MYO6 protein has obvious color development, which shows that biotin-modified GP-1 can be used for the detection of membrane hybridization MYO6 protein. At the same time, it can also be proved that the nucleic acid aptamer GP-1 can be used to accurately detect at least 75μg / ml of MYO6 protein.
[0123] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0124] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A nucleic acid aptamer that binds to MYO6 protein, characterized in that: The sequence of the nucleic acid aptamer includes: the nucleotide sequence shown in SEQ ID NO.1 or 2; Preferably, the sequence of the nucleic acid aptamer is shown as SEQ ID NO.1 or SEQ ID NO.
2.
2. A nucleic acid aptamer that binds to MYO6 protein, characterized in that: The nucleic acid aptamer comprises any one of the following sequences: 1) a nucleotide sequence having at least 30%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99% homology to the nucleotide sequence shown in SEQ ID NO. 1 or 2; 2) RNA sequence transcribed from the nucleotide sequence shown in SEQ ID NO. 1 or 2; 3) A sequence that can hybridize with the nucleotide sequence shown in SEQ ID NO. 1 or 2.
3. The nucleic acid aptamer according to claim 1 or 2, characterized in that The nucleic acid aptamer is modified at one or more positions; Preferably, the modification refers to at least one of phosphorylation, methylation, amination, sulfhydrylation, replacement of oxygen with sulfur, replacement of oxygen with selenium, and isotopization.
4. A nucleic acid aptamer conjugate or derivative binding to MYO6 protein, characterized in that: The nucleic acid aptamer conjugate or derivative contains the nucleic acid aptamer according to any one of claims 1 to 3; Preferably, the conjugate is formed by connecting the nucleic acid aptamer according to any one of claims 1 to 3 to a label; Preferably, the label connected to the nucleic acid aptamer includes a radioactive substance, a therapeutic substance, a biotin label, an enzyme label, a fluorescein label, a nucleic acid probe, a nanoluminescent material, a small peptide or siRNA; Preferably, the derivative is formed by modifying the nucleic acid aptamer according to any one of claims 1 to 3; Preferably, the modification includes a phosphorothioate backbone derived from the backbone of the nucleotide sequence of the nucleic acid aptamer; or a peptide nucleic acid modified from the nucleotide sequence of the nucleic acid aptamer.
5. A method for screening a nucleic acid aptamer that binds to MYO6 protein, characterized in that: The following steps are involved: (1) synthesizing a random single-stranded DNA library and providing primers, wherein the DNA library includes a random single-stranded DNA as shown in TCCAGCACTCCACGCATAAC-36N-GTTATGCGTGCTACCGTGAA, wherein 36N represents a sequence formed by connecting 36 arbitrary nucleotide bases; the sequences of the primers are shown in SEN ID NOs. 3 to 6; (2) Magnetic bead screening: Perform at least 4 rounds of counter-screening and screening, and add serum starting from the 4th round.
6. A product for detecting MYO6 protein, characterized in that: The product contains the nucleic acid aptamer according to any one of claims 1 to 3, or the nucleic acid aptamer conjugate or derivative according to claim 4, or a nucleic acid aptamer screened by the method according to claim 5; Preferably, the product includes a preparation, a test strip, a test kit, a chip or a chromatographic detection device.
7. A product for purifying MYO6 protein, characterized in that: The product contains the nucleic acid aptamer according to any one of claims 1 to 3, or the nucleic acid aptamer conjugate or derivative according to claim 4, or a nucleic acid aptamer screened by the method according to claim 5; Preferably, the product includes a preparation, a test strip, a test kit, a chip or a chromatographic detection device.
8. A drug for treating a disease caused by abnormal expression of MYO6 protein, characterized in that: Contains the nucleic acid aptamer according to any one of claims 1 to 3, or the nucleic acid aptamer conjugate or derivative according to claim 4, or a nucleic acid aptamer screened by the method according to claim 5.
9. Use of the nucleic acid aptamer according to any one of claims 1 to 3, the nucleic acid aptamer conjugate or derivative according to claim 4, or the nucleic acid aptamer screened by the method according to claim 5 in the preparation of a product for detecting or purifying MYO6 protein; Preferably, the product is a preparation, a test strip, a test kit, a chip or a chromatographic detection device.
10. Use of the nucleic acid aptamer according to any one of claims 1 to 3, the nucleic acid aptamer conjugate or derivative according to claim 4, or the nucleic acid aptamer screened by the method according to claim 5 in the preparation of a drug for treating a disease caused by abnormal expression of MYO6 protein.
Citation Information
Cited By
Type VI myosin related antigen epitope peptide and application thereof
CN122187941A
